Objective: To compare the bioavailability of 2 sertraline tablets formulations (Tolrest from Laboratorios Biosintetica, and Zoloft from Laboratorios Pfizer, Brazil) in 24 healthy volunteers of both sexes (12 male and 12 female) who received a single 50 mg dose of each sertraline formulation. Material and methods: The study was conducted open with randomized two-period crossover design and a 14-day washout period. Plasma samples were obtained over a 96-hour interval and sertraline concentrations were analyzed by combined reversed phase liquid chromatography and tandem mass spectrometry (LC-MS-MS) with positive ion electrospray ionization using selected ion monitoring method. From the plasma sertraline concentration vs. time curves the following pharmacokinetic parameters were obtained: AUC((0-96) (h)), AUC((0-∞)), C(max), C(max)/AUC((0-96) (h)), T(max), ke, and t(1/2). Results: Pharmacokinetic parameters presented normal distribution according to Probit's plot and Kolmogorov Smirnov's test, and the variance of AUC((0-96) (h)), AUC((0-∞)) or C(max) were homoscedastic. Geometric mean Tolrest/Zoloft individual percent ratio was 95.22% for AUC((0-96) (h)), 99.87% for C(max), 100.4% for AUC((0-∞)), 103.6% for Ke, 96.0% for t(1/2) and 93.7% for T(max). Conclusion: Since the 90% CI for both C(max) and AUC((0-96) (h)) mean ratio were within the 80-125% interval proposed by the Food and Drug Administration, it was concluded that Tolrest was bioequivalent to Zolof for both extent and rate of absorption in a single dose administration.

Comparative bioavailability of two sertraline tablet formulations in healthy human volunteers after a single dose administration.

CORSO, GAETANO;
1998-01-01

Abstract

Objective: To compare the bioavailability of 2 sertraline tablets formulations (Tolrest from Laboratorios Biosintetica, and Zoloft from Laboratorios Pfizer, Brazil) in 24 healthy volunteers of both sexes (12 male and 12 female) who received a single 50 mg dose of each sertraline formulation. Material and methods: The study was conducted open with randomized two-period crossover design and a 14-day washout period. Plasma samples were obtained over a 96-hour interval and sertraline concentrations were analyzed by combined reversed phase liquid chromatography and tandem mass spectrometry (LC-MS-MS) with positive ion electrospray ionization using selected ion monitoring method. From the plasma sertraline concentration vs. time curves the following pharmacokinetic parameters were obtained: AUC((0-96) (h)), AUC((0-∞)), C(max), C(max)/AUC((0-96) (h)), T(max), ke, and t(1/2). Results: Pharmacokinetic parameters presented normal distribution according to Probit's plot and Kolmogorov Smirnov's test, and the variance of AUC((0-96) (h)), AUC((0-∞)) or C(max) were homoscedastic. Geometric mean Tolrest/Zoloft individual percent ratio was 95.22% for AUC((0-96) (h)), 99.87% for C(max), 100.4% for AUC((0-∞)), 103.6% for Ke, 96.0% for t(1/2) and 93.7% for T(max). Conclusion: Since the 90% CI for both C(max) and AUC((0-96) (h)) mean ratio were within the 80-125% interval proposed by the Food and Drug Administration, it was concluded that Tolrest was bioequivalent to Zolof for both extent and rate of absorption in a single dose administration.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11369/5381
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 11
social impact